Inmunoteràpia per la prevenció I tractament de la infecció ...€¦ · • Higher incidence of...
Transcript of Inmunoteràpia per la prevenció I tractament de la infecció ...€¦ · • Higher incidence of...
Inmunoteràpia per la prevenció I tractament de la infecció pel VIHBeatriz Mothe, MD, PhD
HIV Unit, Infectious Diseases Department. IrsiCaixa AIDS Research Institute
Hospital Germans Trias i Pujol, Badalona.
XXVIII Jornades de la Societat Catalana de Malalties Infeccioses i Microbiologia Clínica
2 SCMIMC_20191026
• Basics in immunology• What’s new in prevention?• Are we closer to an HIV cure?
3 SCMIMC_20191026
Infectious Disease vs Immune Disease of a viral origin
⬆ Viral escape to CTLsProgressive exhaustion of CTLs:
⬇Effector Functions⬇ Proliferation Capacity
4 SCMIMC_20191026CD8
TLRsNLRCLRsRLRs
PRR:
FcRsTCR
Cytokines
Antigen presentation
Fc
Cell
NeutralizationBlocking
Antibody-dependent cellular cytotoxicity(ADCC)
Antibody-Dependent Cellular Phagocytosis(ADCP)
Cell lysis mediated by complement SCMIMC_20191026Courtesy J. Carrillo
bNAbs functions (not only block!)
Infected cell
Infected cell
ViralPeptides
(epitopes)
HLAClass Ialleles
CD8
T cellReceptor
Antiviralcytokines
and lytic granules
Adapted from B.Walker
CTL Killing
5 SCMIMC_20191026
6 SCMIMC_20191026
T cells are not alone : Immunological synapse
7
Immunotherapies for cancer
https://cincodias.elpais.com/cincodias/2018/03/12/companias/1520881368_939672.html SCMIMC_20191026
8 SCMIMC_20191026
Preventive Strategies Cure Strategies• Avoid HIV acquisition after exposure, but• If infection occurs
- to limit its spread - enable HIV control- avoid progression- limit transmission to others
• Achieve complete elimination of HIV• If HIV persists
- enhable HIV control- avoid progression- limit transmission to othersO
BJEC
TIVE
S
• bNAbs to block/neutralize virions• T cells to eliminate infected cells
• Reactivate viral reservoir (Kick & Kill)• T cells to eliminate infected cells
ACTO
RS
• ‘HEALTHY’ Immune system• Need to tackle huge HIV diversity worldwide
• ‘UN-HEALTHY’ & Exhausted Immune system• Pre-existing non-efficacious responses• Ability of the virus to escape to CTL pressureHO
STImmunotherapies in HIV
9 SCMIMC_20191026
Preventive Strategies Cure Strategies• Avoid HIV acquisition after exposure, but• If infection occurs
- to limit its spread - enable HIV control- avoid progression- limit transmission to others
• Achieve complete elimination of HIV• If HIV persists
- enhable HIV control- avoid progression- limit transmission to othersO
BJEC
TIVE
S
• bNAbs to block/neutralize virions• T cells to eliminate infected cells
• Reactivate viral reservoir (Kick & Kill)• T cells to eliminate infected cells
ACTO
RS
• ‘HEALTHY’ Immune system• Need to tackle huge HIV diversity worldwide
• ‘UN-HEALTHY’ & Exhausted Immune system• Pre-existing non-efficacious responses• Ability of the virus to escape to CTL pressureHO
ST
1 Main hurdles for preventive vaccines
Huge global viral diversity
All HIV-1 subtypes, sub-subtypes, CRF
HIV-infected patient
One HIV-1 subtype
Annual global Influenza A
Adapted from McCutchan F. and Korber B., Brit Med Bull 2001; Hemelear 2004, WHO/UNAIDS10 SCMIMC_20191026
ABCDF, G, H, J, KCRF01_AE
other
CRF02_AGCRF03_AB
Subtype
HIV genomes differ by 10-30% whilstsHuman genomes differ by about 0.1%
1 Main hurdles for preventive vaccines
Low ammount of envelope spikes / virionAccess to binding sites due to sugar shield
11 SCMIMC_20191026Schiller 2014
12 SCMIMC_20191026
Several bNAbs already in NHP or clinical testing
Sok, Burton 2019 Passive administration!!
13 SCMIMC_20191026
First preventive vax with a positive (weak) Efficacy signalThai trial
16,000 HIV negs>3y follow-up$$$$$$$$$$$$$
Phase III
1
Rerks-Ngarm NEJM 2009, Haynes B, NEJM 2012
RV144 ‘Thai’ Trial (2009)
low risk population
First preventive vax with a positive (weak) Efficacy signalThai trial
Phase III
14 SCMIMC_20191026
1
Barouch, Lancet HIV 201815 SCMIMC_20191026
Since then, only 1 trial into Phase IIIMOSAICO / HVTN 706
Phase III
1
Protection through both Ab & CTL
Barouch, Lancet HIV 2018
Since then, 1 trial into Phase IIIMOSAICO / HVTN 706
Fase IIB : ongoing Sudafrica, 2600 women (IMBOKODO) Fase III EU, USA, Latinamerica (2019, 3800, MOSAICO) Expected efficacy data 2023
16 SCMIMC_20191026
Phase III
17
Not sterilizing but induction of control post-infection
• Interventions studies in the SIV model suggests post-intervention control is attainable- CMV-vectored vaccines inducing 50% of control after infection
• However, mechanisms are also quite unclear and a CMV intervention difficult to translate into humans
Hansen 2011/2013
CMV-vectored vaccines suggest role of MHC class II & HLA-E restricted responses
SCMIMC_20191026
18 SCMIMC_20191026
Preventive Strategies Cure Strategies• Avoid HIV acquisition after exposure, but• If infection occurs
- to limit its spread - enable HIV control- avoid progression- limit transmission to others
• Achieve complete elimination of HIV• If HIV persists
- enhable HIV control- avoid progression- limit transmission to othersO
BJEC
TIVE
S
• bNAbs to block/neutralize virions• T cells to eliminate infected cells
• Reactivate viral reservoir (Kick & Kill)• T cells to eliminate infected cells
ACTO
RS
• ‘HEALTHY’ Immune system• Need to tackle huge HIV diversity worldwide
• ‘UN-HEALTHY’ & Exhausted Immune system• Pre-existing non-efficacious responses• Ability of the virus to escape to CTL pressureHO
ST
ART does not cure HIV
No new transmissions
ART
Circ
ulat
ing
Viru
s
Limit of detection
TimeVIRAL RESERVOIR
19 SCMIMC_20191026
20
T cell vaccines as the backbone of any HIV cure strategy‘We aim to eliminate HIV infected cells. And this is what CTL do’
SCMIMC_20191026
21
T cell vaccines as the backbone of any HIV cure strategy
LRA Vaccine
Vaccines+ ’Reactivators’ of the viral reservoir
Vaccines aloneIn early-treated individualsw/ new vaccine candidates
Vaccines + Immunotherapies to • improve CTL functionality, • enhance CD4 T help, • ADCC, etc
‘Personalized’ strategies
SCMIMC_20191026
22 Years
pVL
CD4
pVL
CD4
pVL
CD4
Spontaneous Control(EC/VC)
Post-intervention Control??
Post-Treatment Controllers
?
Which T cell immune Response? Models of HIV control
SCMIMC_20191026
23
Years
pVL
CD4
pVL
CD4
pVL
CD4
• Lower peak viremia • Less symptomatic ARS
• Maintain suppressed viremia without ART• Able to mantain low levels of reservoir• Usually do not transmit (but potentially could)
Leon 2016, Blankson 2007, O’Conell 2010, Ostrowski 2008, Hunt 2008, Pereyra 2009, Pereyra 2012, Crowel 2016, Li 2019, Avettand-Fenoel 2019
BUT• Can progress / lose control (up to 35%?)
• Generally harbor replication competent virus and haveevidence of ongoing viral replication and evolution
• Higher levels of immune activation and inflamation comparedto ART-suppressed
• Higher incidence of non-AIDS related diseases (CV)
• Higher all-cause hospitalizations
• Non-sterilizing immunity Can be superinfected by HIV
Not a perfect model!
Spontaneous HIV control (EC / VC / LTNP)
SCMIMC_20191026
24
Combined mechanisms of Spontaneous HIV control
HOST
VIRUS IMMUNE RESPONSE
HLA-BDelta-32 CCR5rs 9039999 SNP in the HLA C
HETEROGENEOUS GROUP
SCMIMC_20191026
• GWAS studies with signal in Chromosome 6 (HLA genes) associated with EC
• Class I loci (HLA-A, -B and -C) associated with HIV control
25 Fellay, 2007; O’Brien 2001; Rosas-Umbert 2018
Host - HLA
SCMIMC_20191026
26
Characteristics of T cell responses in controllers
LANL SCMIMC_20191026
27
CTL specificity matters
Frahm 2004, Zuñiga 2006, Betts 2006, Mothe 2011, Mothe 2015
• Relative Gag dominance
• Several specific HIV targets enriched in
controllers in Gag, but also in Pol, Vif & Nef
• Not only if Good HLA! base of HTI vaccine
CTL immune screens in >1000 HIV+
Time (years)
pVL
CD4
pVL
CD4
pVL
CD4
SCMIMC_20191026
28
Functionality
Betts 2006, Julg 2010, Saéz-Cirion 2007, Chen 2009, Hanckok 2015, Pereyra 2014; Mothe 2019
• Polyfunctionality of T-cells
• Maintain high viral inhibition capacity by CD8
SCMIMC_20191026
29 Hocini 2019
Gene expression in controllers
• Up regulation of T-cell activation gene expression
• Low inflammation
• Down modulation of NK inhibitory cell signaling
Role of NK function?
SCMIMC_20191026
30 Okulicz 2009, Leon 2016, Pernas 2018, Rosas-Umbert 2018
What do we know about losing HIV control (LoC Critical for the longevity of vaccine-induced response!
N=14 ‘losers’
SCMIMC_20191026
31
LoC associated with increased activation and exhaustion
Rosas-Umbert 2018
• Same HLA as long-term EC/VC
• Change to CXCR4 viruses after LoC in few individuals
• Only 1 case of superinfection
• No evidence of increased CTL escape by viral sequencing Pre-Post LoC
• No loss of Gag dominance
SCMIMC_20191026
32
LoC preceeded by a lower suppressive capacity
Rosas-Umbert 2018, Koofhethile 2016 SCMIMC_20191026
33
Post-Treatment controllers (PTC)
• After first isolated reports first group – the VISCONTI Cohort (n=14) in early-treated individuals (NOT ACUTE)
• CHAMP Metaanalysis of 700 ATI patients from – 67 PTC
• <13% early-cART (within 6 months from acquisition) & <4% in Chronic-treated
Salgado 2011, Saez-Cirion 2013, Sneller 2018, Namazi 2018
‘Non-rebounders’ ‘Post-rebound controllers’
Up to 30%
SCMIMC_20191026
34
Post-Treatment controllers (PTC)• Mechanisms still unclear BUT seems to be different from ‘classical’ spontaneous
controllers:
• Not enriched in Beneficial HLA alleles for suppressive CTL response ( B35)• Have history of high viral loads before ART or during previous ATI • Not show ‘classical’ strong CD8 T cells Polyfunctional HIV-specific CD4 T
cells (closer to Early-treated rather than controllers)
• Are also able to maintain low reservoir levels different cell subsets?
Salgado 2011, Saez-Cirion 2013, Samri 2016
CD4
CD8
SCMIMC_20191026
35 Years
pVL
CD4
pVL
CD4
pVL
CD4
Spontaneous Control(EC/VC)
Post-intervention Control??
Post-Treatment Controllers
?
Post-Intervention control?
SCMIMC_20191026
36
Post-Intervention controllers ??- Therapeutic Vaccines + TLR7 agonist in ART-treated (acute) CD8 responses associated with lower setpoint
and delayed rebound
Borducci 2016, Borducci 2018
- TLR7 agonist + PGT 121 bNAb in ART-treated (acute) CD8 depletion rise pVL ONLY in post-rebound controllers (≄ mechanisms!)
SCMIMC_20191026
37
- Combination of 10-1074 + 3BNC117 in acute infection (no ART) CD8 mediated without ‘classical’ controller phenotype probable role of CD4 T help Preserve functional initial CD8 T cell response to limit reservoir seeding
Nishimura 2017 SCMIMC_20191026
Post-Intervention controllers ??
38
- BCN02 Kick&Kill CT in early-treated individuals
MVA1 MVA2RMD1-3 Monitored Antiretroviral Pause (MAP) cART Ressumption Phase
-4 01
3 4 5 6 910 13 17 +4wk +12wk
+24wkweeks>2,000 cp/ml
(x2)
MAP1-32
Mothe & Rosas-Umbert, submitted 2019 SCMIMC_20191026
Post-Intervention controllers ??LRA Vaccine
39
Additional effect of ICB?
- Vaccine-induced responses in early-treated can be increased in vitro by ICB
Marin, Garcia-Prado, unpublished
ChronicChro (n=11)
Early treated vaccinatedEtVac (n=11)
Early treatedEt (n=12)
HIV-1 infected individuals
HIV-1 Gag peptide poolHIV-1 vaccine peptide pool
Proliferation (CFSE-)IFN-production
HLADR+/38+
Isotype PD-1 TIM-3α α
SCMIMC_20191026
40
Additional effect of ICB?
Marin, Garcia-Prado, unpublished
Proliferation
IFNg
Activation
- Impact of αPD-1 and αTIM3 in HIV-1 specific-CD8+ T cell responses in ET-Vac& Chro (not in ET alone!)
SCMIMC_20191026
1
26 beneficial HIV targets
Time (years)
HIV pVL
CD4
pVL
CD4
pVL
CD4
Mothe JTM 2011; Mothe Plos ONE 2012
New therapeutic vaccinesBased on natural HIV control (HTI)
41 SCMIMC_20191026
1
Phase I/II: ongoing at Can Ruti (n=45: 30 Vax + 15 Pbo) Early_treated Phase II: Vax + TLR7 agonist, multisite. Expectes start Q1 2020
RESULTS EXPECTED 2020/2022 . AELIX THERAPEUTICS
New therapeutic vaccinesBased on natural HIV control (HTI)
42 SCMIMC_20191026
43
TAKE-HOME messages
• HIV/AIDS as an immune disease
• World wide diversity and ability to escape the immune pressure as main hurdles.
• Need to build on a non-efficacious pre-existing immune response to HIV bypassing the immunosuppressive status
• Need to either re-direct/educate this previously inefficient response (shift CTL immunodominance patterns) &/or
induce novel specificities all together ,
• Need to improve functionality of T-cells (killing) and make it long-lasting!
• Need to tackle CTL-driven escape capacity (already contained in most proviruses in Chro)
• CD8 CTL do not work alone! Require helper CD4 T cells & a non-exhausted environment Immunotherapies
• T cell vaccines as the backbone of any prevention and HIV cure strategy
SCMIMC_20191026
bNAbs + T cell vaccines
44
LRA Vaccine
T cell vaccines+ ’Reactivators’ of the viral reservoir
T cell Vaccines aloneIn early-treated individualsw/ new vaccine candidates
T cell Vaccines + Immunotherapies to • improve CTL functionality, • enhance CD4 T help, • ADCC, etc
Preventive Strategies
Cure Strategies
Cure Strategies
Cure Strategies
SCMIMC_20191026
Jose MoltóLucía BailónMiriam LópezCristina MirandaPatricia CobarsíJessica ToroRoser Escrig
BRANDER LABChristian BranderMiriam Rosas-UmbertMarta Ruiz-RiolAnuska LlanoSamandhy CedeñoBruna OriolSandra SilvaAlex OlveraClara DuranLuis Romero
Javier Martinez-PicadoM. Carmen PuertasAngel BayonSara Morón-López
Julia Garcia-PradoMiguel MarínAlba Ruiz
Roger ParedesBonaventura Clotet
ALL STUDY PARTICIPANTS!!!